A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
NCT ID: NCT01529528
Last Updated: 2013-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
117 participants
INTERVENTIONAL
2011-05-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Therapeutic Exploratory Study of CWP-0403
NCT00888719
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
NCT04632862
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
NCT02121717
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
NCT01129258
Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
NCT04014023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo of CWP-0403 100mg
Placebo of CWP-0403 100mg
Placebo of Anagliptin
Placebo of Anagliptin 100mg, tablet, BID
CWP-0403 200mg
CWP-0403 200mg
Anagliptin
Anagliptin 100mg, tablet, BID
CWP-0403 100mg
CWP-0403 100mg
Anagliptin
Anagliptin 100mg, tablet, BID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anagliptin
Anagliptin 100mg, tablet, BID
Anagliptin
Anagliptin 100mg, tablet, BID
Placebo of Anagliptin
Placebo of Anagliptin 100mg, tablet, BID
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit
* FPG ≤ 270mg/dL at screening visit
* Patients who consent to participate in this trial by written Informed Consent Form
Exclusion Criteria
* Subjects who are administrating insulin or need to insulin therapy
* History of oral anti-hyperglycemic drugs within 6 weeks before screening visit
* Body mass index \< 20 kg/m2 or \> 40.0kg/m2
* Subjects who are assessed to be inappropriate for this trial by investigator
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sung Woo Park, M.D., PhD
Role: PRINCIPAL_INVESTIGATOR
Kangbuk Samsung Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kangbuk Samsung Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CWP-DIANA-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.